NCT03621696已完成2 期
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 63
- 试验地点
- 2
- 主要终点
- Mean Percent Weight Change
研究概览
简要总结
The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed HPV-related stages I-III OPSCC (8th edition of AJCC/UICC Staging Manual) or HPV-related neck node with unknown primary. HPV-related may be defined by p16 IHC stain and/or HPV-ISH or PCR using standard definitions of positive and negative test results.
- •Primary tumor that will be resected via a transoral oral approach (conventional surgery, transoral laser microsurgery, transoral robotic surgery)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-
- •Normal organ and marrow function defined as:
- •Creatinine clearance > 50 cc/min.
- •ANC > 1,000/mcL.
- •Platelet count >100,000/mcL.
- •At least 18 years of age.
- •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.
排除标准
- •Prior curative therapy for HNSCC.
- •Patient must not have known distant metastatic disease at presentation.
- •History of prior invasive malignancy diagnosed within 2 years prior to study enrollment; exceptions are malignancies with a low risk of metastasis or death (e.g., expected 5-year overall survival (OS) > 90%) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of T1a or T1b).
- •Receiving any other investigational agents.
- •Uncontrolled serious inter-current illness or serious psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant and/or breastfeeding. A negative serum or urine pregnancy test is required at screening for all female patients of childbearing potential.
研究组 & 干预措施
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Surgery (Procedure)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Neck Dissection Impairment Index (Other)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Intensity modulated radiation therapy (Radiation)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Cisplatin (Drug)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Intensity modulated radiation therapy (Radiation)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Intensity modulated proton therapy (Radiation)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: FACT-H&N (Other)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: MD Anderson Dysphagia Inventory (Other)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: University of Michigan Xerostomia Index (Other)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Scale of Subjective Total Taste Acuity (Other)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Intensity modulated proton therapy (Radiation)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Surgery (Procedure)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: FACT-H&N (Other)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: MD Anderson Dysphagia Inventory (Other)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: University of Michigan Xerostomia Index (Other)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Scale of Subjective Total Taste Acuity (Other)
Arm 2: POAmRT
Experimental
- Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Neck Dissection Impairment Index (Other)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Intensity modulated radiation therapy (Radiation)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Intensity modulated proton therapy (Radiation)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Surgery (Procedure)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: FACT-H&N (Other)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: MD Anderson Dysphagia Inventory (Other)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: University of Michigan Xerostomia Index (Other)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Scale of Subjective Total Taste Acuity (Other)
Arm 3: POACRT
Experimental
- Patients with clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)
- The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Neck Dissection Impairment Index (Other)
Arm 1: POAmCRT
Experimental
- Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
- Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
- Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
- It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
- Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study
干预措施: Cisplatin (Drug)
结局指标
主要结局
Mean Percent Weight Change
时间窗: Starting at Day 1 and ending on the last day of radiation therapy (approximately 4 weeks)
* Weight in kilograms will be collected weekly during radiation * The percent weight loss from the baseline is calculated at any post-baseline
次要结局
- Change in Serum Creatinine(Baseline to 6 weeks after POAmCRT (approximately 90 days))
- Percentage of Participants Taking Narcotics(6 weeks after POAmCRT (approximately 90 days))
- Overall Survival (OS)(Through completion of follow-up (approximately 63 months))
- Proportion of PEG Tube Placements in Each Arm(Through completion of follow-up (approximately 63 months))
- Progression-free Survival (PFS)(Through completion of follow-up (approximately 63 months))
- Disease Recurrence Rate(24 months post-treatment (approximately 27 months))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic CancerCancer of PancreasUnresectable Pancreatic CancerChemotherapy EffectSBRTNCT03891472Medical University of Silesia40
已完成
2 期
Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesAcute Lymphoblastic Leukaemias (ALL)Acute Myeloid Leukaemias (AML)Myelodysplastic Syndromes (MDS)Juvenile Myelomonocytic Leukaemias (JMML)NCT02333058medac GmbH70
暂停
2 期
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaStomach AdenocarcinomaGastro-esophageal Junction CancerNCT06728657Fudan University68
招募中
2 期
Study of a Novel Type 1 Oral Poliomyelitis Vaccine in BangladeshPoliomyelitisNCT05644184PATH2,232
已完成
1 期
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver ProblemsHealthyHepatic InsufficiencyNCT03842761Boehringer Ingelheim64